Work

A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction.

Year: 2022

Type: review

Study designs: Systematic Review, Meta-Analysis

Abstract: BACKGROUND: Heart failure with preserved ejection fraction is a complex clinical syndrome marked by different phenotypes and related comorbidities. Transthyretin amyloidosis is an underestimated phenotype. We aim to evaluate the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. METHODS: This meta-analysis was conducted according to PRISMA guidelines. A search strategy was designed to utilize PubMed/Medline, EMBASE, and Google scholar to locate studies whose primary objective was to analyze the prevalence of transthyretin amyloidosis in heart failure preserved ejection fraction. RESULTS: =87%) compared with transthyretin negative group. CONCLUSION: Transthyretin amyloidosis affects 11% of HFpEF patients. Therefore, screening HFpEF patients at risk of cardiac amyloidosis is warranted.

Source: PubMed

Authors: Mohamed Magdi, Mostafa Reda Mostafa, Waiel Abusnina, Ahmad Al-Abdouh, Ramy Doss, Sarah Mohamed, Chidera Philippa Ekpo, Richard Alweis, Bipul Baibhav

Institutions: Unity Health System, Creighton University, University of Kentucky, Baylor University Medical Center, Cairo University, Rochester General Hospital

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Internal Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4288064325

FWCI: 0.989

Cites: 43

Cited by: 24

Related to: 10